Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Verdict

Headline takes no side. We score NRIX +1.00 across four claims — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · NRIX

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 98% of ticker scores this week

What matters in this story